Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

  title={Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum},
  author={Gajanan N. Sapkal and Pragya Dhruv Yadav and Raches Ella and Gururaj R. Deshpande and Rima R. Sahay and Nivedita Gupta and Vadrevu Krishna Mohan and Priya Abraham and Samiran Panda and Balram Bhargava},
We performed the plaque reduction neutralization test (PRNT50) using sera collected from the recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape. 
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1-CoV-2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively.
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein
Emerging SARS-CoV-2 variants of concern and potential intervention approaches
The major variant of concerns (VOCs) have shared mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins, mostly on the S1 unit and resulted in higher
Comparison of the pathogenicity and virus shedding of SARS CoV-2 VOC 202012/01 and D614G variant in hamster model
SARS-CoV-2 VOC 202012/01 infected hamsters demonstrated high viral RNA shedding through the nasal secretions and significant body weight loss with mild lung pathology compared to the D614G variant.
Efficacy of Vaccine and Administration of Vaccine for all the Individuals against SARS-CoV-19 and the Variants
The efficacy of different designed drug for SARS-CoV-2 has been much of debate from the approval and till date after roll out and the administration of vaccination differences with age factor of over approved vaccines asserted inductively.
This review article gives detailed information about the study of India’s first Indigenous COVID-19 vaccine “COVAXIN” and gets more information about its preclinical study, formulation, as well as its safety and efficacy in various phases of clinical trials.
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
In vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern, and other strains are summarized to provide guidance for the treating physician.
SARS-CoV-2 variants, spike mutations and immune escape
The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets.
An Update on the Leading COVID-19 Vaccines
This work reviewed the COVID-19 vaccines that reached phase III of clinical development and described the technology used for vaccine development, available data from phase III clinical trials, data on vaccine safety, and the role of new SARS-CoV-2 variants on vaccine efficacy.
Vaccine efficacy in mutant SARS-CoV-2 variants.
There is a need to review current treatment vaccination guideline and strategy as early as possible and draw the attention of health care provider, and all developed countries health care agencies including WHO, to frame new guidelines for vaccination and immediate intervention to control the development of new SARS-CoV-2 variants from the third world countries.


SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma and suggest that SARS has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed.
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients
In the early stages of infection, the NAb response was observed with variable antibody kinetics, and neutralization assays can be used for titration of NAb in recovered/vaccinated or infected COVID-19 patients.
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
Interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152, 3{ micro} and 6{micro} with Algel-IMDG suggest that the safety profile of this vaccine is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
An interactive visualization and open analysis pipeline is presented to facilitate use of the dataset for vaccine design and functional annotation of mutations observed during viral surveillance.
New variant of SARS-CoV-2 in UK causes surge of COVID-19
  • T. Kirby
  • Medicine
    The Lancet Respiratory Medicine
  • 2021
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152
  • medRxiv
  • 2020
    In a 1st, NIV-Pune isolates, cultures Covid's UK variant